Document Type

Article

Publication Date

1-13-2026

Comments

This article, originally published by Dove Medical Press, is the author’s final published version in Journal of Asthma and Allergy, Volume 19, 2026, Pages 1-12.

The published version is available at https://doi.org/10.2147/JAA.S564966. Copyright © 2026 Lugogo et al.

 

Abstract

Purpose: We aimed to describe the disease burden of asthma and examine relationships between short-acting beta-2 agonist (SABA) use and asthma exacerbations. Patients and Methods: This retrospective cohort study used geographically diverse Premier Healthcare Database (PHD) and linked insurance claims (10/01/2021-09/30/2022) for US patients aged ≥18 years with a SABA-only prescription and a history of asthma exacerbation within 12 months before index date (the earliest SABA prescription date). Three asthma control groups were defined based on SABA usage: well controlled-low (0–1 prescriptions), not well controlled-medium (2–3 prescriptions), very poorly controlled-high (≥4 prescriptions). Four asthma severity groups were defined using asthma medication usage: intermittent, mild persistent, moderate persistent, and severe persistent. Results: A total of 12,692 patients were included: mean age 38.7 years, 73% female, 54% white, 31% Black, and 70% Medicaid patients. During the 12-month post-index period, 31% (n = 3,889) experienced an exacerbation at a mean rate 0.51 (SD 1.05) per patient. The percentage of patients with low, medium, and high SABA-only prescriptions were 42%, 21%, and 37%, respectively. A greater proportion of high-SABA users had an asthma exacerbation (41%) versus medium- (32%) or low- (20%) SABA users (both p < 0.0001). The proportion of patients with asthma maintenance controller use was the highest (71%) among high-SABA users, followed by medium- (56%), and low- (35%) SABA users (all p < 0.0001). Mean rates of asthma exacerbation during 12-month post-index period were 0.34 (SD 0.75) in the intermittent, 0.43 (SD 0.87) in the mild persistent, 0.43 (SD 0.82) in the moderate persistent, and 0.73 (SD 1.37) in the severe persistent groups (p < 0.0001). Almost a quarter (24%) of patients with intermittent asthma experienced an exacerbation during this period. Conclusion: Patients with greater use of SABA-only rescue inhalers experienced higher rates of exacerbations, despite having greater asthma controller use. New rescue therapy approaches are needed to decrease the burden of illness in asthma patients.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Language

English

Download

Share

COinS